UroGen Pharma Ltd.
URGN
$29.80
-$1.53-4.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 52.92% | 21.45% | 8.00% | 10.85% | 8.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.92% | 21.45% | 8.00% | 10.85% | 8.98% |
| Cost of Revenue | 50.33% | 40.15% | 33.73% | 25.48% | 7.47% |
| Gross Profit | 53.22% | 19.41% | 5.23% | 9.21% | 9.15% |
| SG&A Expenses | 4.85% | -0.59% | 67.32% | 70.58% | 70.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.33% | -1.98% | 63.00% | 63.95% | 64.17% |
| Operating Income | 20.21% | -0.34% | -92.35% | -89.77% | -95.89% |
| Income Before Tax | -2.25% | -23.68% | -45.18% | -37.55% | -34.77% |
| Income Tax Expenses | -260.44% | -97.25% | -25.64% | 5.33% | -19.81% |
| Earnings from Continuing Operations | 3.76% | -20.98% | -42.70% | -36.43% | -32.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.76% | -20.98% | -42.70% | -36.43% | -32.70% |
| EBIT | 20.21% | -0.34% | -92.35% | -89.77% | -95.89% |
| EBITDA | 20.90% | 0.31% | -91.87% | -90.68% | -97.41% |
| EPS Basic | 10.08% | -6.68% | -18.50% | -5.87% | 7.40% |
| Normalized Basic EPS | 23.62% | 13.10% | -47.28% | -31.62% | -16.94% |
| EPS Diluted | 10.08% | -6.68% | -18.50% | -5.87% | 7.40% |
| Normalized Diluted EPS | 23.62% | 13.10% | -47.28% | -31.62% | -16.94% |
| Average Basic Shares Outstanding | 7.42% | 12.30% | 18.54% | 29.42% | 40.91% |
| Average Diluted Shares Outstanding | 7.42% | 12.30% | 18.54% | 29.42% | 40.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |